YHYi-Jun Hua

Yi-Jun Hua

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yi-Jun Hua has a total of 148 co-authors. Here are the top co-authors by number of shared publications:

  • Ming-Yuan Chen

    State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, P.R. China; Department of Nasopharyngeal Carcinoma, The Fifth Affiliated Hospital Sun Yat-sen University, Zhuhai 519000, P.R. China; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou 510060, P.R. China

    9 shared publications
  • Xiong Zou

    Department of Nasopharyngeal Carcinoma Sun Yat‐Sen University Cancer Center Guangzhou China

    9 shared publications
  • Rui You

    Nasopharyngeal Cancer Center The Fifth Affiliated Hospital, Sun Yat‐Sen University Zhuhai China

    7 shared publications
  • Si-Yuan Chen

    Department of Nasopharyngeal Carcinoma, The Fifth Affiliated Hospital Sun Yat-sen University, Zhuhai 519000, P.R. China

    7 shared publications
  • You-Ping Liu

    Department of Nasopharyngeal Carcinoma, The Fifth Affiliated Hospital Sun Yat-sen University, Zhuhai 519000, P.R. China

    6 shared publications
  • Pei-Yu Huang

    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China

    5 shared publications

Latest Publications

  • Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma: CSCO and ASCO Joint Guideline

    by Wei Jiang, Nofisat Ismaila, Melvin Lk Chua, Robert Haddad, Quynh-Thu Le, A. Dimitrios Colevas, Nabil F Saba, Kevin Harrington, Shao Hui Huang, Anthony Tc Chan, et al.

    PURPOSE: To provide evidence-based recommendations on first- and subsequent-line systemic therapy, maintenance therapy, locoregional consolidation, and salvage local therapy for patients with recurrent and/or metastatic nasopharyngeal carcinoma (NPC). METHODS: A multidisciplinary Expert Panel convened by CSCO and ASCO reviewed evidence from randomized trials, meta-analyses, systematic reviews, prospective and retrospective studies, and clinical experience. The guideline was informed by a systematic literature review and consensus-based interpretation of efficacy, safety, feasibility, and patient-centered outcomes across scenarios. Outcomes included overall and progression-free survival, response and disease control rates, toxicity, and quality of life. RESULTS: Evidence supports platinum-based chemotherapy plus a programmed cell death protein 1 (PD-1) inhibitor as preferred first-line therapy for medically fit patients. Evidence also supports maintenance strategies after disease control, while treatment selection depends on prior treatment, disease extent, patient fitness, resource availability, and preferences. Selected responders may receive locoregional consolidation radiotherapy or oral maintenance chemotherapy. For isolated locoregional recurrence amenable to local therapy, options include salvage surgery and re-irradiation. RECOMMENDATIONS: Chemotherapy plus a PD-1 inhibitor, followed by maintenance PD-1 inhibition for up to 2 years, should be offered first-line to appropriate patients with recurrent and/or metastatic NPC. Chemotherapy alone may be offered when immunotherapy is unsuitable or declined. Selected patients responding to first-line chemotherapy may receive oral maintenance chemotherapy or locoregional consolidation intensity-modulated radiotherapy. Salvage surgery or re-irradiation is recommended for appropriately selected patients with isolated locoregional recurrence. Subsequent-line options include chemotherapy, PD-1 inhibitors, and antibody-drug conjugates. Treatment should be individualized according to disease setting, prior therapy, expected toxicities, availability, local drug approvals, and patient preferences. Early supportive and specialist interdisciplinary palliative care, where available, should accompany active anticancer treatment for advanced, incurable disease. Additional information is available at www.ascopubs.org/topics/asco-guidelines/head-neck-cancer .

  • A Surgical Map Defining High‐Risk Anatomical Boundaries for Salvage Endoscopic Nasopharyngectomy

    by Lanxi Li, Zihan Qin, Qilun Guo, Zhaohui Shi, Weijing Zhang, Youping Liu, Rui You, Xiong Zou, Jibin Li, Huifeng Li, et al.

    Objective: Salvage endoscopic nasopharyngectomy has emerged as a viable option for selected patients with recurrent nasopharyngeal carcinoma. However, the absence of an evidence‐based anatomical framework to guide surgical decision‐making limits optimal patient selection and contributes to postoperative recurrence. Methods: We retrospectively analyzed 421 patients with recurrent nasopharyngeal carcinoma who underwent salvage endoscopic nasopharyngectomy between January 2012 and December 2023. Tumor invasion patterns were systematically assessed to identify anatomical sites independently associated with local recurrence, which were subsequently integrated into a surgical map defining high‐risk anatomical boundaries. Results: With a median follow‐up of 46.0 months, the 5‐year overall survival and local recurrence‐free survival were 79.8% and 68.2%, respectively. Multivariable analysis identified several anatomical regions significantly associated with inferior local recurrence‐free survival, including tumor proximity to the internal carotid artery (< 0.5 cm [HR, 2.813; 95% CI, 1.471–5.380]), pterygomaxillary fossa (HR, 3.181; 95% CI, 1.478–6.845), sphenoid sinus (HR, 3.080; 95% CI, 1.307–7.259), posterior cortex of the clivus (HR, 1.906; 95% CI, 1.021–3.560), foramen lacerum (HR, 2.354; 95% CI, 1.281–4.325), and inferior tumor extension below the axis (HR, 4.611; 95% CI, 1.713–12.410). Patients with involvement of these high‐risk areas exhibited markedly lower 5‐year overall survival (64.3% vs. 85.8%; p < 0.001) and local recurrence‐free survival (26.1% vs. 85.1%; p < 0.001) compared with those without high‐risk features. Based on these findings, an evidence‐based surgical map was constructed. Conclusion: We propose a surgical map that defines high‐risk anatomical boundaries for salvage endoscopic nasopharyngectomy in recurrent nasopharyngeal carcinoma. This framework provides a practical decision‐support tool to improve oncologic outcomes. Level of Evidence: 3.

  • Association of glycaemic control with post-radiation nasopharyngeal necrosis in diabetic patients with nasopharyngeal carcinoma

    by Lanxi Li, Ziying Wang, Zihan Qin, Zesheng Cai, Weijing Zhang, Xiong Zou, Peiyu Huang, Jian Li, Yijun Hua

  • Open Access

    TQB2450 plus intensity-modulated radiotherapy in recurrent nasopharyngeal carcinoma: An open-label, single-arm, phase II trial

    by Tian-Liang Xia, Wenxuan Huang, You-Ping Liu, Zheng-Kai Feng, Si-Yuan Chen, Xi Ding, Lan Peng, Wen-Bin Wu, Ding Yu, An-Qi Yang, et al.

  • Open Access

    Predictive value of nasopharyngeal microbiota for necrosis after re-irradiation in recurrent nasopharyngeal carcinoma

    by Kai Wen, Ze-Rong Huang, Yong-Long Liu, Wen-Bin Wu, Zi-Han Qin, Yan-Feng Ouyang, Xiong Zou, Rui You, You-Ping Liu, Ming-Yuan Chen, et al.

    Background: Post-radiation nasopharyngeal necrosis (PRNN) is a severe complication following re-irradiation in patients with recurrent nasopharyngeal carcinoma (NPC). This study aimed to explore the association between nasopharyngeal microbiota and PRNN in patients with recurrent NPC undergoing re-irradiation and to evaluate the predictive value of the microbiota for PRNN. Methods: This retrospective study collected data from 113 patients with recurrent NPC who underwent re-irradiation at the Sun Yat-sen University Cancer Center (SYSUCC) between January 2020 and November 2022. Patients were divided into necrosis and non-necrosis groups based on the development of necrosis after re-irradiation. 5R 16S rRNA sequencing of nasopharyngeal biopsy tissues conducted before re-irradiation was used to assess microbiota composition, diversity, and functional predictions. Clinical features and selected microbial markers were used in a random forest model to predict the occurrence of PRNN. Results: Of the 113 patients with recurrent NPC who underwent re-irradiation, 60 developed PRNN, while 53 did not. Proteobacteria and Firmicutes were the dominant phyla in the nasopharyngeal microbiota of all the patients with recurrent NPC. The necrosis group exhibited significantly higher alpha diversity and distinct beta diversity than the non-necrosis group did. A predictive model that combined clinical features (gross tumor volume [GTV]) with microbiome characteristics achieved an AUC of 87.9% in the training set and 86.9% in the test set, demonstrating robust predictive performance. Conclusions: Nasopharyngeal microbial diversity prior to re-irradiation was significantly higher in the necrosis group. Our predictive model, integrating clinical and microbial features, demonstrated strong performance in predicting PRNN and offers a promising tool for early intervention and prevention strategies.


  • Open Access

    Nasopharyngeal carcinoma detected noninvasively in the real world using three gene methylation analyses from automatically processed bilateral nasal swab samples

    by Zi-Han Qin, Si-Yuan Chen, Shuai Zhou, Hua Deng, Lan-Xi Li, Qi-Lun Guo, Xiong Zou, Pei-Yu Huang, Ming-Yuan Chen, Liang Zhang, et al.

    Background: Efforts have been made to improve the performance of nasopharyngeal carcinoma screening strategies, which include EBV related biomarkers. However, the advances achieved still remain imperfection. DNA methylation occurs early in cancer development and can be used as potential diagnostic biomarker. This study aimed to investigate the diagnostic performance of three methylated genes in nasopharyngeal carcinoma (NPC) patients. Methods: A total of 255 nasopharyngeal swabs and 35 plasma samples were collected from patients with newly diagnosed or treated NPC and healthy controls. Methylation-specific PCR (MSP) was used to evaluate the methylation levels of three genes (SEPTIN9, RASSF1A, and H4C6) in swabs and plasma samples. The methylation rates, sensitivity, and specificity of the candidate genes were calculated. Furthermore, the detectability of methylated genes in paired swabs and plasma was compared. Results: The detection rate of methylated SEPTIN9, RASSF1A, and H4C6 in nasopharyngeal swabs of patients with newly diagnosed NPC was 88.2%, 92.9% and 71.8%, respectively, while it reduced to 54.3%, 42.9% and 45.7% in blood plasma. The sensitivity of detecting methylated SEPTIN9, RASSF1A, and H4C6 to distinguish between untreated NPC and healthy controls was 88%, 93%, and 72%, respectively. Methylated RASSF1A showed the highest classification accuracy (AUC = 0.956). The detection rate of the methylated target genes was considerably lower in paired plasma samples. Conclusion: The detection of RASSF1A methylation through non-invasive nasopharyngeal cavity swab sampling demonstrates significant potential for NPC diagnosis.


  • Open Access

    Incidence of mastoiditis in nasopharyngeal carcinoma following anti-PD-1 therapy: A propensity-matched analysis

    by Qi-Lun Guo, Yong-Long Liu, Wei-Jing Zhang, Kai Wen, Hui-Feng Li, Rui You, Si-Yuan Chen, Jian Li, Ming-Yuan Chen, Yi-Jun Hua

    Mastoiditis can be induced by radiotherapy and is closely associated with hearing loss. This study aimed to investigate the incidence of mastoiditis in patients with locally advanced nasopharyngeal carcinoma (LANPC) undergoing anti-programmed death 1 (PD-1) therapy. We retrospectively reviewed patients with primary locoregionally advanced nasopharyngeal carcinoma who received intensity-modulated radiotherapy and concurrent cisplatin-based chemotherapy with or without anti-PD-1 therapy from January 2020 to January 2022 in a single medical institution. Group A received neoadjuvant chemotherapy (NACT) + concurrent chemoradiotherapy (CCRT) + anti-PD-1 therapy, whereas Group B received the same treatment, except for anti-PD-1 therapy. We employed a propensity score matching method to match patients from each group in a 1:1 ratio. The severity of mastoiditis was assessed using magnetic resonance imaging, specifically grading mastoid opacification on a scale of 0 – 3. A total of 136 out of 259 eligible patients were propensity-matched, with 68 patients in Group A and 68 patients in Group B. No significant differences were observed in patient and tumor characteristics between the two groups. There were no significant differences in the incidence rates of severe mastoiditis between the two groups before NACT, before CCRT, at 0 months, and at 3 months following CCRT. However, the incidence rate of severe mastoiditis at 6 months following CCRT was significantly higher in Group A compared to Group B (35.3% vs. 20.6%, P = 0.008). Analysis of variance with repeated measures demonstrated that anti-PD-1 therapy did not increase the incidence rate of severe mastoiditis in LANPC patients compared to immunotherapy-free patients following CCRT (P = 0.24). LANPC patients receiving anti-PD-1 therapy did not significantly experience more severe mastoiditis during CCRT, but there was an increasing trend post-CCRT. Additional follow-up with a larger patient cohort is necessary to draw definitive conclusions.

  • Open Access

    Noninvasive detection of early nasopharyngeal carcinoma based on three gene methylation analysis in bilateral nasal swab samples processed automatically

    by Zi-Han Qin, Si-Yuan Chen, Shuai Zhou, Hua Deng, Lan-Xi Li, Qi-Lun Guo, Xiong Zou, Pei-Yu Huang, Ming-Yuan Chen, Liang Zhang, et al.

    Background Efforts have been made to improve the performance of nasopharyngeal carcinoma screening strategies, including EBV related biomarkers. However, the advances achieved still remain imperfect. DNA methylation occurs early in cancer development and can be used as potential diagnostic biomarker. This study aimed to investigate the diagnostic performance of three methylated genes in patients with nasopharyngeal carcinoma (NPC). Methods 255 nasopharyngeal swabs and 35 plasma samples were collected from patients with newly diagnosed or treated NPC and healthy controls. Methylation-specific PCR (MSP) was carried out to evaluate the methylation status of three genes (SEPTIN9, RASSF1A, and H4C6) in the swabs and plasma samples. Methylation rates, sensitivity, and specificity of the candidate genes were calculated. Furthermore, the detectability of methylated genes in paired swabs and plasma was compared. Results In the nasopharyngeal swabs of patients with newly diagnosed NPC, the detection rate of methylated SEPTIN9, RASSF1A, and H4C6 was 88.2%, 92.9% and 71.8%, while the rate decreased to 54.3%, 42.9% and 45.7% by blood plasma, respectively. The sensitivity of detecting methylated SEPTIN9, RASSF1A, and H4C6 to differentiate between untreated NPC, and treated NPC plus healthy controls was 88%, 93%, and 72%. Methylated RASSF1A showed the best classification accuracy (AUC = 0.956). The detection rate of the target methylated genes was significantly lower in the paired plasma samples. Conclusion The detection of RASSF1A methylation through non-invasive nasopharyngeal cavity swab sampling demonstrates significant potential in NPC diagnosis.


  • Open Access

    A phase 2 trial of gemcitabine plus toripalimab for cisplatin-ineligible patients with recurrent or metastatic nasopharyngeal carcinoma

    by Xiong Zou, Xi Ding, Zheng-Kai Feng, Yan-Feng Ouyang, Hui-Feng Li, Kai Wen, Zhi-Qiang Wang, You-Ping Liu, Yong-Long Liu, Wei-Jing Zhang, et al.


  • Assessment of Prophylactic Internal Carotid Artery Management in Postradiation Nasopharyngeal Necrosis Patients

    by Yong‐Long Liu, Kai Wen, Wei‐Jing Zhang, Yan‐Feng Ouyang, Jin‐Hua Chen, Yang‐Kui Gu, Qi Mei, Ming‐Yuan Chen, Yi‐Jun Hua, Jian Li

    Objective: Postradiation nasopharyngeal necrosis (PRNN) frequently develops after second‐course radiotherapy for nasopharyngeal carcinoma (NPC). PRNN can lead to internal carotid artery (ICA) massive hemorrhage due to ICA rupture, resulting in sudden death. This study aims to explore the pretreatment of the ICA to prevent fatal massive hemorrhage in PRNN patients.Study Design: Retrospective cohort study.Setting: Sun Yat‐sen University Cancer Center.Methods: Patients diagnosed with NPC and PRNN from January 2010 to September 2022 were included. The Cox proportional hazards regression analysis was performed to analyze risk factors for massive hemorrhage and survival. A nomogram was developed to integrate prognostic models and perform parameter calibration.Results: Two hundred and fifty‐four PRNN patients were included in this study. Prophylactic ICA occlusion significantly reduced the risk of ICA hemorrhage compared to no prophylactic ICA occlusion (3.6% vs 40.6%, P < .001). Surgical repair on necrosis significantly prevented hemorrhage and improved survival. The nomogram, incorporating the above 2 factors and the nearest distance from necrosis to ICA ≤ 3 mm, exhibited excellent discriminative ability for hemorrhage. We identified 3 high‐risk factors that indicate the need for prophylactic ICA management in PRNN patients: (1) exposure of ICA by rhinoscopy; (2) signs of ICA erosion on MRA scanning; (3) the depth of soft tissue coverage surrounding the ICA wall within the necrotic cavity is less than 3 mm on magnetic resonance imaging.Conclusion: We have identified 3 high‐risk factors for PRNN patients that necessitate prophylactic ICA management. These findings are expected to contribute to improving the quality of life and overall survival of PRNN patients.